A Biogen funded, pan-European study published in BioDrugs found that SB5 (Imraldi®), biosimilar to AbbVie’s Humira® (adalimumab), to be effective and well tolerated in patients with rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and Crohn’s disease. The paper noted that “particular consideration should perhaps be given to female patients who are considering switching, since they appear to be more susceptible to discontinuation than their male counterparts”.
SB5 was first approved by the FDA on 24 July 2019; and was launched in the US by Samsung and Organon on 1 July 2023 as Hadlima® at a list price of $1038, an 85% discount compared to Humira®. Biogen is commercialising SB5 as Imraldi® in Europe.